Literature DB >> 21514658

Long-term protection against malaria after experimental sporozoite inoculation: an open-label follow-up study.

Meta Roestenberg1, Anne C Teirlinck, Matthew B B McCall, Karina Teelen, Krystelle Nganou Makamdop, Jorien Wiersma, Theo Arens, Pieter Beckers, GeertJan van Gemert, Marga van de Vegte-Bolmer, André J A M van der Ven, Adrian J F Luty, Cornelus C Hermsen, Robert W Sauerwein.   

Abstract

BACKGROUND: We have shown that immunity to infection with Plasmodium falciparum can be induced experimentally in malaria-naive volunteers through immunisation by bites of infected mosquitoes while simultaneously preventing disease with chloroquine prophylaxis. This immunity was associated with parasite-specific production of interferon γ and interleukin 2 by pluripotent effector memory cells in vitro. We aim to explore the persistence of protection and immune responses in the same volunteers.
METHODS: In an open-label study at the Radboud University Nijmegen Medical Centre (Nijmegen, Netherlands), from November to December, 2009, we rechallenged previously immune volunteers (28 months after immunisation) with the bites of five mosquitoes infected with P falciparum. Newly recruited malaria-naive volunteers served as infection controls. Our primary outcome was the detection of blood-stage parasitaemia by microscopy. We assessed the kinetics of parasitaemia with real-time quantitative PCR (rtPCR) and recorded clinical signs and symptoms. In-vitro production of interferon γ and interleukin 2 by effector memory T cells was studied after stimulation with sporozoites and red blood cells infected with P falciparum. Differences in cellular immune responses between the study groups were assessed with the Mann-Whitney test. This study is registered with ClinicalTrials.gov, number NCT00757887.
FINDINGS: Four of six immune volunteers were microscopically negative after rechallenge. rtPCR-based detection of blood-stage parasites in these individuals was negative throughout follow-up. Patent parasitaemia was delayed in the remaining two immunised volunteers. In-vitro assays showed the long-term persistence of parasite-specific pluripotent effector memory T-cell responses in protected volunteers. The four protected volunteers reported several mild to moderate adverse events, of which the most commonly reported symptom was headache (one to three episodes per volunteer). The two patients with delayed patency had adverse events similar to those in the control group.
INTERPRETATION: Artificially induced immunity lasts longer than generally recorded after natural exposure; providing a new avenue of research into the mechanisms of malaria immunity. FUNDING: Dioraphte Foundation.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21514658     DOI: 10.1016/S0140-6736(11)60360-7

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  132 in total

1.  Vaccines: The take-home lesson.

Authors:  Sarah DeWeerdt
Journal:  Nature       Date:  2012-04-25       Impact factor: 49.962

Review 2.  Systems immunology of human malaria.

Authors:  Tuan M Tran; Babru Samal; Ewen Kirkness; Peter D Crompton
Journal:  Trends Parasitol       Date:  2012-05-15

Review 3.  Looking under the skin: the first steps in malarial infection and immunity.

Authors:  Robert Ménard; Joana Tavares; Ian Cockburn; Miles Markus; Fidel Zavala; Rogerio Amino
Journal:  Nat Rev Microbiol       Date:  2013-10       Impact factor: 60.633

Review 4.  Malaria immunity in man and mosquito: insights into unsolved mysteries of a deadly infectious disease.

Authors:  Peter D Crompton; Jacqueline Moebius; Silvia Portugal; Michael Waisberg; Geoffrey Hart; Lindsey S Garver; Louis H Miller; Carolina Barillas-Mury; Susan K Pierce
Journal:  Annu Rev Immunol       Date:  2014       Impact factor: 28.527

5.  Effector Phenotype of Plasmodium falciparum-Specific CD4+ T Cells Is Influenced by Both Age and Transmission Intensity in Naturally Exposed Populations.

Authors:  Michelle J Boyle; Prasanna Jagannathan; Katherine Bowen; Tara I McIntyre; Hilary M Vance; Lila A Farrington; Bryan Greenhouse; Felistas Nankya; John Rek; Agaba Katureebe; Emmanuel Arinaitwe; Grant Dorsey; Moses R Kamya; Margaret E Feeney
Journal:  J Infect Dis       Date:  2015-02-02       Impact factor: 5.226

Review 6.  Immune mechanisms in malaria: new insights in vaccine development.

Authors:  Eleanor M Riley; V Ann Stewart
Journal:  Nat Med       Date:  2013-02       Impact factor: 53.440

Review 7.  Chemical Attenuation in the Development of a Whole-Organism Malaria Vaccine.

Authors:  Amber I Raja; Danielle I Stanisic; Michael F Good
Journal:  Infect Immun       Date:  2017-06-20       Impact factor: 3.441

Review 8.  Live attenuated pre-erythrocytic malaria vaccines.

Authors:  Gladys J Keitany; Marissa Vignali; Ruobing Wang
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

Review 9.  Murine infection models for vaccine development: the malaria example.

Authors:  Kai Matuschewski
Journal:  Hum Vaccin Immunother       Date:  2012-12-18       Impact factor: 3.452

10.  AID expression in peripheral blood of children living in a malaria holoendemic region is associated with changes in B cell subsets and Epstein-Barr virus.

Authors:  Joel R Wilmore; Amolo S Asito; Chungwen Wei; Erwan Piriou; P Odada Sumba; Iñaki Sanz; Rosemary Rochford
Journal:  Int J Cancer       Date:  2014-08-19       Impact factor: 7.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.